Guangxi Wuzhou Zhongheng Group Co.,Ltd

Equities

600252

CNE0000015F9

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
2.44 CNY +3.83% Intraday chart for Guangxi Wuzhou Zhongheng Group Co.,Ltd +8.93% -2.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd commences an Equity Buyback for CNY 200 million worth of its shares, under the authorization approved on March 28, 2024. CI
Guangxi Honggui Capital Operation Group Co.,Ltd. agreed to acquire 18% stake in Guangxi United Asset Management Co., Ltd from Guangxi Wuzhou Zhongheng Group Co.,Ltd for approximately CNY 190 million. CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug MT
Wuzhou Zhongheng’s Drug For Preventing Chemotherapy-Related Nausea Passes Consistency Test MT
Sealand Securities Co., Ltd. announced that it has received CNY 3.192189985 billion in funding from a group of investors CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) added to S&P Global BMI Index CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) added to FTSE All-World Index CI
Wuzhou Zhongheng Gets Nod to Trial Ovarian Cancer Drug MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangxi Wuzhou Zhongheng Receives 42 Million Yuan in Government Subsidy MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Restrictions on Guangxi Wuzhou Zhongheng Drugs in 2022 Chinese Drug Catalogue Amended MT
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) dropped from S&P Global BMI Index CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd(XSSC:600252) dropped from FTSE All-World Index CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beibu Gulf Property & Casualty Insurance Co.,Ltd. announced that it expects to receive CNY 450 million in funding from Guangxi Wuzhou Zhongheng Group Co.,Ltd CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart Guangxi Wuzhou Zhongheng Group Co.,Ltd
More charts
GUANGXI WUZHOU ZHONGHENG GROUP CO., LTD is a China-based company, principally engaged in the manufacture of pharmaceuticals and food production. The Company's pharmaceuticals include cardiovascular drugs, medicine for bruises, gynecology medication and other general drugs. The Company also provides Chinese herbal jelly products, Chinese herbal beverages and others. The Company is also engaged in the development of real estate, including the development and sales of commercial housings and stores. The Company mainly conducts its businesses within domestic market and to overseas markets.
More about the company
  1. Stock Market
  2. Equities
  3. 600252 Stock
  4. News Guangxi Wuzhou Zhongheng Group Co.,Ltd
  5. Restrictions on Guangxi Wuzhou Zhongheng Drugs in 2022 Chinese Drug Catalogue Amended